We are excited to announce that Parent Project Muscular Dystrophy and Sarepta Therapeutics are joining forces on a genetic testing program for patients with Duchenne or Becker muscular dystrophy. Through the new genetic testing program, called Decode Duchenne, PPMD will provide testing at no cost to eligible patients who are unable to access testing due to barriers such as a lack of or insufficient insurance coverage. Sarepta is supporting the PPMD-administered initiative.
We believe all patients with Duchenne should have the opportunity to receive genetic testing in order to understand their genetic mutation, have confidence in their diagnosis, and learn about opportunities to participate in clinical trials. This program seeks to address barriers to genetic testing in Duchenne that have long frustrated healthcare providers, patients and their families.
The Decode Duchenne genetic testing program is expected to launch before the end of 2013 through PPMD's DuchenneConnect, an online resource and registry for patients and families affected by Duchenne and their healthcare providers.
To participate in Decode Duchenne, patients must:
Receive Launch Notification
Please ensure that your child is registered with DuchenneConnect in order to take advantage of the Decode Duchenne program and receive updates on its launch. Thank you to Sarepta Therapeutics for supporting this important initiative!
Together we will end Duchenne.